医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BestWeek Asia-Pacific: GCC Takaful Regulation Lags Behind Market Growth

2013年01月29日 AM05:55
このエントリーをはてなブックマークに追加


 

HONG KONG

While the takaful industry has been developing rapidly in the countries of the Gulf Cooperation Council, the development of takaful regulation varies significantly country by country, according to a new special report featured in BestWeek Asia-Pacific. As a result, the levels of policyholder protection differ from one state to another, which has created opportunities for takaful operators to pursue regulatory arbitrage.

Indeed, there is significant debate as to the right level of regulation. Market participants in some of the more demanding regimes consider the regulations to be stifling their companies. A.M. Best believes the solution is not less regulation but more consistent application of regulation throughout the region, which has the potential to provide sufficient policyholder protection, and thus safeguard the long-term viability of the takaful industry.

Also featured in BestWeek Asia-Pacific, a look at how widening health protection gaps in China are creating an opening and potential major role for private individual medical insurance to fill the gap. Health care spending is projected to grow from US$357 billion in 2011 to US$1 trillion in 2020, according to consultancy McKinsey & Co. Cigna Corp. told BestWeek Asia-Pacific the sustainability of the commercial group medical insurance market remains a big concern to many insurers in China, paving the way for private individual medical insurance to “play an important supplementary role” in health care reform.

The Jan. 29 edition is available at www.bestweek.com/asia and www.bestweek.com.

BestWeek is published by A.M. Best Co. for insurance professionals. To subscribe, visit www.ambest.com/sales/BestWeek.

BestWeek can be accessed on iPads and mobile devices at www.bestweek.com. On your iPad or mobile device, click on BestWeek digital to log in.

Founded in 1899, A.M. Best Co. is the world’s oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com.

Copyright © 2013 by A.M. Best Company, Inc. ALL RIGHTS RESERVED.

CONTACT

A.M. Best Co.
Iris Lai, +(852) 2827 3400
iris.lai@ambest.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent